Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press121210.17650/1726-9776-2005-1-2-27-31DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫPartial Cystectomy for Invasive Bladder CancerОрганосохраняющее лечение при инвазивном раке мочевого пузыряMickischG. H.МикичД. Х.
Germany

Бремен

Центр оперативной урологии Бремена, Академический госпиталь «Links der Weser»300620051227312002202020022020https://oncourology.abvpress.ru/oncur/article/view/1212

Background. Radical cystectomy with pelvic lymph node dissection is the standard treatment for patients with invasive bladder cancer. However, many alternative techniques to spare the bladder have been investigated. Single-center, non-randomized studies have reported good patient’s acceptance and reasonably good treatment outcomes.

Methods. We review the experience reported in the literature on bladder-sparing techniques, including transurethral resection, chemotherapy, radiation, and multimodality approaches for muscle-invasive disease focussing on controlled clinical trials.

Results. Most comparative studies indicate that local recurrence and survival outcomes for bladder-sparing approaches are inferior to those from radical cystectomy to control muscle-invasive bladder cancer.

Conclusions. Although molecular biologic techniques may have the capacity to identify a subgroup of patients who may benefit from a bladder-sparing approach, cystectomy is normally required for optimal results. Nevertheless, several alternatives to radical cystectomy for muscle-invasive bladder cancer have been studied. None, however, are reliably superior to radical operative treatment.

.

1. Shipley W.U., Kaufman D.S., Heney N.M. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy // J. Urol. — 1999;162:445—451.Shipley W.U., Kaufman D.S., Heney N.M. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy // J. Urol. — 1999;162:445—451.2. Sternberg C.N., Arena M.G., Calabresi F. Neoadjuvant MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder // Cancer. — 1993;72:1975—1982.Sternberg C.N., Arena M.G., Calabresi F. Neoadjuvant MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder // Cancer. — 1993;72:1975—1982.3. Rivera I., Wajsman Z. Bladder-sparing treatment of invasive bladder cancer // Cancer Contr. — 2000; 7:340—346.Rivera I., Wajsman Z. Bladder-sparing treatment of invasive bladder cancer // Cancer Contr. — 2000; 7:340—346.4. Kim H.L., Steinberg G.D. The current status of bladder preservation in the treatment of muscle invasive bladder cancer // J. Urol. — 2000; 164: 627—632.Kim H.L., Steinberg G.D. The current status of bladder preservation in the treatment of muscle invasive bladder cancer // J. Urol. — 2000; 164: 627—632.5. Solsona E., Iborra I., Ricos J.V. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term follow-up of a prospective study // J. Urol. — 1998;159:95—99.Solsona E., Iborra I., Ricos J.V. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term follow-up of a prospective study // J. Urol. — 1998;159:95—99.6. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors // J. Urol. — 1999;162:74—76.Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors // J. Urol. — 1999;162:74—76.7. Holzbeierlein J.M., Lopez-Corona E., Bochner B.H. et al. Partial cystectomy: a con-temporaray review of the Memorial-Sloan-Kettering Cancer Center experience and recommendations for patient selection // J. Urol. — 2004; 172: 878—881.Holzbeierlein J.M., Lopez-Corona E., Bochner B.H. et al. Partial cystectomy: a con-temporaray review of the Memorial-Sloan-Kettering Cancer Center experience and recommendations for patient selection // J. Urol. — 2004; 172: 878—881.8. Montie J.E. Against bladder sparing: surgery // J. Urol. — 1999; 162:452—457.Montie J.E. Against bladder sparing: surgery // J. Urol. — 1999; 162:452—457.9. Kuczyk M., Turkeri L., Hammerer P., Ravery V. Is there a role for bladder preserving strategies in the treatment of muscle-unvasive bladder cancer? // Eur. Urol. — 2003; 44: 57—64.Kuczyk M., Turkeri L., Hammerer P., Ravery V. Is there a role for bladder preserving strategies in the treatment of muscle-unvasive bladder cancer? // Eur. Urol. — 2003; 44: 57—64.10. Holmang S., Hedelin H., Borghede G. Long-term follow up of a bladder carcinoma cohort: questionable value of radical radiotherapy // J. Urol. — 1997;157:1642—1646.Holmang S., Hedelin H., Borghede G. Long-term follow up of a bladder carcinoma cohort: questionable value of radical radiotherapy // J. Urol. — 1997;157:1642—1646.11. Eapen L., Stewart D., Crook J. Intraarterial cisplatin (IAC) and concurrent pelvic radiation (PR) in the management of transitional bladder cancer: an organ preservation strategy. Proc. Annu Meet. Am. Soc. Clin. Oncol. — 1995;14:A625.Eapen L., Stewart D., Crook J. Intraarterial cisplatin (IAC) and concurrent pelvic radiation (PR) in the management of transitional bladder cancer: an organ preservation strategy. Proc. Annu Meet. Am. Soc. Clin. Oncol. — 1995;14:A625.12. Wijnmaalen A., Helle P.A., Koper P.C. et al. Muscle invasive bladder cancer treated by transurethral resection followed by external beam radiation and interstitial iridium-192 // Int. J. Radiat. Oncol. Biol. Phys. — 1997;39:1043—1052.Wijnmaalen A., Helle P.A., Koper P.C. et al. Muscle invasive bladder cancer treated by transurethral resection followed by external beam radiation and interstitial iridium-192 // Int. J. Radiat. Oncol. Biol. Phys. — 1997;39:1043—1052.13. Shipley W.U., Winter K.A., Kaufman D.S. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 // J. Clin. Oncol. — 1998;16:3576—3583.Shipley W.U., Winter K.A., Kaufman D.S. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 // J. Clin. Oncol. — 1998;16:3576—3583.14. Gschwend J.E., Vieweg J., Fair W.R. Disease specific survival after radical cystectomy // J. Urol. — 1997;157:1662A.Gschwend J.E., Vieweg J., Fair W.R. Disease specific survival after radical cystectomy // J. Urol. — 1997;157:1662A.15. Cheng L., Neumann R.M., Scherer B.G. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion // Cancer. — 1999;85:2638—2647.Cheng L., Neumann R.M., Scherer B.G. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion // Cancer. — 1999;85:2638—2647.16. Hart S., Skinner E.C., Meyerowitz B.E. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit,cutaneous or urethral kock pouch // J. Urol. — 1999; 162:77—81.Hart S., Skinner E.C., Meyerowitz B.E. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit,cutaneous or urethral kock pouch // J. Urol. — 1999; 162:77—81.